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Objectives This study sought to determine the optimal coronary revascularization strategy in patients with diabetes with
severe coronary disease.
Background Although subgroup analyses from large trials, databases, and meta-analyses have found better survival for pa-
tients with diabetes with complex coronary artery disease when treated with surgery, a randomized trial compar-
ing interventions exclusively with drug-eluting stents and surgery in patients with diabetes with high-risk coronary
artery disease has not yet been reported.
Methods In a prospective, multicenter study, 198 eligible patients with diabetes with severe coronary artery disease were
randomly assigned to either coronary artery bypass grafting (CABG) (n  97) or percutaneous coronary interven-
tion (PCI) with drug-eluting stents (n  101) and followed for at least 2 years. The primary outcome measure
was a composite of nonfatal myocardial infarction or death. Secondary outcome measures included all-cause
mortality, cardiac mortality, nonfatal myocardial infarction, and stroke.
Results The study was stopped because of slow recruitment after enrolling only 25% of the intended sample size, leaving it severely
underpowered for the primary composite endpoint of death plus nonfatal myocardial infarction (hazard ratio: 0.89; 95%
confidence interval: 0.47 to 1.71). However, after a mean follow-up period of 2 years, all-cause mortality was 5.0% for
CABG and 21% for PCI (hazard ratio: 0.30; 95% confidence interval: 0.11 to 0.80), while the risk for nonfatal myocardial
infarction was 15% for CABG and 6.2% for PCI (hazard ratio: 3.32; 95% confidence interval: 1.07 to 10.30).
Conclusions This study was severely underpowered for its primary endpoint, and therefore no firm conclusions about the
comparative effectiveness of CABG and PCI are possible. There were interesting differences in the components
of the primary endpoint. However, the confidence intervals are very large, and the findings must be viewed as
hypothesis generating only. (Coronary Artery Revascularization in Diabetes; NCT00326196) (J Am Coll Cardiol
2013;61:808–16) © 2013 by the American College of Cardiology Foundation
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February 26, 2013:808–16 Coronary Revascularization in DiabetesRevascularization Investigation) trial (1), coronary artery
bypass grafting (CABG) was superior to percutaneous
coronary intervention (PCI) at 5-year follow-up. However,
this may not be relevant to the current era, when the use of
drug-eluting stents, glycoprotein IIb/IIIa inhibitors, and
newer oral antiplatelet agents has become standard (2).
Surgical techniques have also evolved since the BARI trial,
with increased use of arterial conduits and off-pump tech-
niques (3). Although the impact of these technical advances
in revascularization has been studied extensively in the
general patient population with multivessel CAD (4–6),
there is a paucity of randomized data concentrating on
patients with diabetes. The BARI 2D trial was not designed
to compare revascularization strategies, and the Future
Revascularization Evaluation in Patients With Diabetes
Mellitus: Optimal Management of Multivessel Disease trial
has completed enrollment but has not yet produced its results. The
CARDIA (Coronary Artery Revascularization in Diabetes)
trial randomized 510 subjects with diabetes between PCI
(with either bare-metal or drug-coated stents) and surgery
and resulted in a composite 1-year rate of death, stroke, and
myocardial infarction (MI) that was similar between CABG
and PCI, but that study was underpowered for this com-
posite endpoint (7).
We conducted a prospective randomized multicenter
study comparing CABG with PCI for severe CAD in
subjects with diabetes, using currently available techniques
for revascularization in the United States. The primary
hypothesis of this study was that a strategy of initial surgical
revascularization is superior to percutaneous intervention in
preventing death or MI in patients with diabetes with severe
ischemic heart disease.
Methods
The trial was conducted at U.S. Department of Veterans
Affairs (VA) medical centers in the United States with a 1:1
randomization between treatment arms. Patients were en-
rolled at 22 sites between August 26, 2006, and March 24,
2010. Patients were eligible if they had diabetes and either
multivessel disease including the left anterior descending
coronary artery or isolated proximal left anterior descending
coronary artery disease. Objective evidence of ischemia was
required for stenoses between 50% and 70%. Ischemia was
documented by stress testing, flow wire, intracoronary
ultrasound, or dynamic changes on electrocardiography
during a symptomatic episode. An interventional cardiolo-
gist and cardiothoracic surgeon reviewed each case and
determined that either procedure was appropriate. The
World Health Organization definition of diabetes was used
(8). Exclusion criteria were age  18 years, women of
hildbearing potential, inability to give informed consent,
oncomitant cardiac surgery, congenital heart disease, life
xpectancy 2 years, lack of surgical conduit, CABG in the
receding year, class III decompensated or class IV heart
ailure, history of embolic stroke within 6 months, history ofhemorrhagic stroke, history of
gastrointestinal bleeding within
1 month, known sensitivity to
glycoprotein IIb/IIIa inhibitors,
chronic steroid use, bleeding di-
athesis, and acute ST-segment
elevation MI. Angiographic ex-
clusion criteria were chronic total
occlusion in 2 or more territories,
unprotected left main coronary
artery disease, unavailability of
both internal thoracic arteries,
and PCI of a major vessel in a
qualifying territory within 1 year.
The study was funded by the
VA Cooperative Studies Pro-
gram and approved by the insti-
tutional review board at each site. An investigational
device exemption was obtained, and all commercially
available drug-eluting stents were allowed once they were
approved by the U.S. Food and Drug Administration for
use in the study. Treatment crossovers were discouraged
but allowed. Patients could withdraw from the study at
any time.
Randomization was performed by the coordinating center
with stratification by site, insulin use (yes or no) and
glycosylated hemoglobin (HbA1c) (8% vs. 8%). Staged
PCI was considered 1 procedure if all interventions were
declared at randomization and completed within 4 weeks.
The choice of stent was at the operator’s discretion, but a
single stent type per patient was recommended. The left
internal thoracic artery was used whenever possible, and the
anterior descending artery was the recommended recipient.
Cardiac risk factor management was left to the primary care
provider, with recommendations to follow American Col-
lege of Cardiology and American Heart Association guide-
lines. Periprocedural insulin infusions were recommended.
HbA1c  9% or failure to achieve blood glucose  180
mg/dl within 12 h on an insulin drip was an indication for
referral to an endocrinologist, but routine consultations
were discouraged. Recurrent coronary disease was treated at
the physician’s discretion.
Baseline and annual rest nuclear studies were performed
to identify silent MIs. Follow-up visits were scheduled at 4
to 6 weeks after revascularization and then every 6 months.
Electrocardiograms were obtained every 3 months, along
with phone contact to determine health status. Interim
hospitalizations for cardiac-related events were docu-
mented. Quality-of-life measures (Seattle Angina Ques-
tionnaire and EuroQol-5D) were obtained every 6 months.
Adverse events were assessed from time of informed consent
to 30 days after the end of a subject’s participation. A data
monitoring committee reviewed safety and outcome mea-
sures semiannually. A blinded core angiographic laboratory
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CI  confidence interval
HbA1c  glycosylated
hemoglobin
HR  hazard ratio
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coronary intervention
VA  U.S. Department of
Veterans Affairsreviewed all coronary angiograms.
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in both arms. This required a 5-fold increase in creatine
phosphokinase-MB plus diagnostic new Q waves on elec-
trocardiography. During follow-up, new MIs were defined
as either clinical (typical history with diagnostic electrocar-
diography changes and/or enzyme elevations) or silent
(diagnostic changes on serial electrocardiograms or new
fixed defect 20% of the myocardium on nuclear studies).
Secondary endpoints included all-cause mortality, cardiac
death, nonfatal MI, stroke, repeated revascularization, stent
thrombosis, and cardiac-related hospitalization. Stent
thrombosis was defined by the Academic Research Consor-
tium guidelines (9). A 3-member endpoint committee
blinded to treatment assignment adjudicated all MIs and
strokes. Where records related to a death in follow-up were
available, the endpoint committee reviewed them to assign
a presumed cardiac versus noncardiac cause. At the end of
the study, searches of VA death databases were undertaken
to confirm the vital status of all patients at last follow-up
and revealed 6 deaths not otherwise reported. No data
concerning causality was available for these cases.
The primary endpoint was a composite of all-cause
mortality or nonfatal MI. Expected event rates used to
determine sample size were based on data from the VA
cardiac surgery database, VA trials, and other non-VA
trials. A total sample size of 790 (395 in each group) was
projected for the study to have 90% power to detect a 40%
reduction in the primary endpoint with CABG compared
with PCI, using a 2-sided log-rank test at an alpha level of
0.05. The sample size calculation assumed 48 months of
recruitment and minimum follow-up of 24 months.
All statistical analyses were conducted using intent-to-
treat principles. The primary hypothesis was tested using
the Kaplan-Meier method and a 2-sided log-rank test. The
time of follow-up was from randomization to the last visit.
Patients who did not have events were censored at their last
visits. The rates for the primary endpoint were also com-
pared according to pre-specified subgroups (insulin use vs.
no insulin use, HbA1c  8% vs.  8%) using the same
methods. Secondary endpoints were assessed using log-rank
tests. Cox proportional hazards models were used to deter-
mine hazard ratios (HRs) and 95% of confidence intervals
(CIs). SYNTAX (Synergy Between PCI With Taxus and
Cardiac Surgery) scores (10) were assigned by the angio-
graphic core laboratory. Comparisons of demographic char-
acteristics, clinical variables, SYNTAX scores, and medica-
tion use between the primary treatment groups and the PCI
survivors versus nonsurvivors were undertaken using
2-sample student t tests for continuous variables and chi-
square tests or Fisher exact tests as appropriate for
discrete variables. All statistical analyses were 2 sided and
were performed using SAS version 9.2 (SAS Institute
Inc., Cary, North Carolina), with p  0.05 as the
criterion for significance.Results
A total of 6,678 patients with diabetes presenting for cardiac
catheterization were screened by study coordinators (Fig. 1).
Of these, 6,080 (91%) did not meet angiographic require-
ments. Of the remaining patients, 207 (35%) were random-
ized. Of the randomized patients, 103 were assigned to
surgery and 104 to PCI. In March 2010, the data monitor-
ing committee recommended stopping enrollment in the
study because of slow recruitment. At that time, no differ-
ences between treatment groups were evident in either the
primary endpoint or all-cause mortality. Six randomized
patients withdrew from the study before treatment once this
was announced (5 surgery, 1 PCI). Three ineligible patients
were randomized in error because of Health Insurance
Portability and Accountability Act issues or confusion by
local investigators regarding eligibility. A total of 198
patients were available for analysis (97 surgery, 101 PCI).
Eleven patients assigned to surgery and 6 patients assigned
to PCI crossed over to the opposite treatment arm. These
patients were analyzed in their assigned treatment arms.
Follow-up of the enrolled patients continued until October
2010.
Baseline characteristics were similar between the treat-
ment arms (Table 1). There was, however, a higher rate of
previous PCI in the PCI group and a trend toward a
different distribution of left ventricular function scores. The
maximal degree of stenosis and lesion length were also
slightly greater in the PCI group, but not by a clinically
significant degree. The average time from randomization to
completion of treatment was 21.4 days for CABG and 7.4
days for PCI (p  0.001).
After a mean follow-up period of 2 years, all-cause
mortality was 5% for CABG and 21% for PCI (HR: 0.30;
95% CI: 0.11 to 0.80), while the risk for nonfatal MI was
15% for CABG and 6.2% for PCI (HR: 3.32; 95% CI: 1.07
to 10.30). These 2 components of the composite endpoint
offset each other, giving a combined risk for death or
nonfatal MI of 18.4% for CABG and 25.3% for PCI (HR:
0.89; 95% CI: 0.47 to 1.71) (Table 2, Fig. 2). Because the
study was underpowered because of early termination, no
differences were found in either the composite endpoint or
its components for the predefined subgroups on the basis of
HbA1c or insulin use, with the exception of all-cause
mortality (3.5% for CABG vs. 28.3% for PCI, p  0.05) in
the largest subgroup (HbA1c  8%). The study findings
were not altered after adjusting for previous PCI, degree of
stenosis, and lesion length. The study results were also not
altered by eliminating low-volume recruiting sites from the
analysis. There was no clustering of PCI mortality by
specific operator or performance site. An “as treated” anal-
ysis showed results similar to the intention-to-treat analysis,
indicating that the crossover patients did not alter the study
results.
The PCI arm was assessed for characteristics associated
with greater risk for death. The nonsurvivors were slightly
s811JACC Vol. 61, No. 8, 2013 Kamalesh et al.
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cores showed slightly worse ventricular function (p 
0.04). Although no other statistically significant differences
were detected between PCI survivors and nonsurvivors,
there were suggestions of greater clinical severity (previous
MI, greater use of cardiac medications) and more severe
CAD (more 3-vessel disease, more chronic total occlusions,
more bifurcation disease, and a higher rate of previous
coronary revascularization) in the nonsurvivors (Table 3).
There were no differences between PCI survivors and
nonsurvivors in the distributions of SYNTAX scores or
stent brands used. The stents used were Taxus (Boston
Scientific Corporation, Natick, Massachusetts; n  35),
Cypher (Cordis Corporation, Miami Lakes, Florida; n 
20), XIENCE/PROMUS (Abbott Vascular, Santa Clara,
California; n  18), Endeavor (Medtronic, Inc., Minneap-
olis, Minnesota; n 2), mixed drug-eluting stents (n 16),
and mixed bare-metal stents (n  1).
Discussion
Early termination of this study shortened follow-up to a
mean of only 2 years, compared with the planned 3.7 years.
With an accrual period of 44 months and maximum
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8.7% for CABG and 13.6% for PCI (p  0.113) (16).
Cardiac mortality almost doubled for PCI (8.8% vs. 4.8%,
p  0.102). Unlike SYNTAX, our patient population did
ot include patients with left main disease (who may have
etter midterm outcomes with PCI) and had higher rates of
isk factors such as HbA1c, smoking, prior MI, and conges-
tive heart failure.
Only 1 prospective randomized trial (CARDIA) has been
published comparing CABG with PCI exclusively patients
with diabetes, but it used a mix of bare-metal (30%) and
drug-eluting stents (7). The rate of the composite outcome
(death, MI, and stroke) at 1 year was 10.5% for CABG and
13% for PCI, failing to prove noninferiority for PCI (p 
0.39). All-cause mortality was identical at 3.2% and 3.2%.
We observed a survival difference only after 1 year. Early
trials comparing surgical revascularization with medical
management showed that the impact of surgery on survival
may not be apparent for 18 months (17). More recently, the
ASCERT study also showed that surgical benefit is delayed
beyond 1 year (12).
The higher risk for nonfatal MI after surgery than after
PCI in this study resulted in offsetting components of the
composite endpoint. A variable impact of revascularization
on the risk for MI has previously been reported. At 10 years,
surgical patients experienced a higher rate of MI than the
medically treated group in the VA coronary surgery trial, yet
survival was improved in certain groups, suggesting that
transforming large MIs into smaller, nonfatal ones can affect
survival (18).
Two factors influenced our reported incidence of MI.
First, we chose a single definition for MI, which is consis-
tent with what was subsequently adopted by the task force
of the European Society of Cardiology, the American
College of Cardiology Foundation, the American Heart
Association, and the World Heart Federation in 2007 for
infarction associated with bypass surgery (19). BARI 2D
and other trials used divergent definitions of periprocedural
ContinuedTable 1 Continued
Characteristic
CABG Group
(n  97)
PCI Group
(n  101) p
Stenosis (%) 77.6 9.0 82.0 8.2 0.001
Lesion length (mm) 13.4 5.5 15.5 7.1 0.02
Total number of native
lesions
3.6 1.3 3.6 1.7 0.79
SYNTAX score 22.7 10.6 21.5 8.9 0.41
SYNTAX score
Low risk (0–22) 47 (50.5%) 59 (62.1%)
Moderate risk (23–32) 33 (35.5%) 24 (25.3%)
High risk (33) 13 (14.0%) 12 (12.6%) 0.24
Values are mean  SD or n (percentage).
ACE angiotensin-converting enzyme; BMI body mass index; CABG coronary artery bypass
rafting; CHF  congestive heart failure; HbA1c  glycosylated hemoglobin; HDL  high-density
lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction; PCI  percutaneous
coronary intervention; PRN; SYNTAX  Synergy Between PCI With Taxus and Cardiac Surgery.Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
CABG Group
(n  97)
PCI Group
(n  101) p
Age (yrs) 62.1 7.4 62.7 7.1 0.61
Male 96 (99.0%) 100 (99.0%) 1.00
Current smoker 20 (20.6%) 28 (27.7%) 0.16
BMI (kg/m2) 33.0 5.7 32.8 5.7 0.80
MI
None 59 (62.8%) 55 (54.5%)
Acute (24 h) 1 (1.1%) 1 (1.0%)
Recent (4 days) 7 (7.4%) 9 (8.9%)
Remote 27 (28.7%) 36 (35.6%) 0.74
CHF
None 53 (56.4%) 64 (63.4%)
Class I 11 (11.7%) 5 (5.0%)
Class II 23 (24.5%) 23 (22.8%)
Class III 7 (7.4%) 9 (8.9%) 0.85
Angina status
None 30 (31.9%) 27 (26.7%)
Class I 18 (19.1%) 17 (16.8%)
Class II 26 (27.7%) 35 (34.7%)
Class III 13 (13.8%) 15 (14.9%)
Class IV 7 (7.4%) 7 (6.9%) 0.85
Previous PCI 19 (20.2%) 35 (34.7%) 0.03
Previous CABG 1 (1.1%) 3 (3.0%) 0.62
Hypertension 90 (95.7%) 97 (96.0%) 1.00
History of stroke 8 (8.5%) 7 (6.9%) 0.79
Peripheral vascular disease 16 (17.0%) 11 (10.9%) 0.30
Total cholesterol (mg/dl) 156.7 38.1 152.1 39.3 0.40
HDL (mg/dl) 30.8 8.2 32.8 9.5 0.13
LDL (mg/dl) 88.8 31.2 82.7 29.6 0.18
Triglycerides (mg/dl) 221.4 149.4 224.0 254.5 0.93
Glucose (mg/dl) 160.1 58.1 157.3 60.9 0.74
HbA1c (%) 7.8 1.6 8.0 1.9 0.54
Duration of diabetes (yrs) 11.3 9.2 11.2 7.7 0.97
Chronic kidney disease
(eGFR  60 ml/min)
33 (35.1%) 26 (26.0%) 0.17
Left ventricular ejection fraction
Normal (55%) 56 (63.6%) 44 (48.9%)
Mild dysfunction (45%–54%) 18 (20.5%) 27 (30.0%)
Moderate dysfunction (35%–44%) 9 (10.2%) 11 (12.2%)
Severe dysfunction (25%–34%) 2 (2.3%) 8 (8.9%)
Very severe dysfunction (25%) 2 (2.3%) 0 (0.0%) 0.06
Aspirin use 81 (86.2%) 87 (86.1%) 1.00
Clopidogrel or ticlopidine use 20 (21.3%) 24 (23.8%) 0.73
Statin use 80 (85.1%) 91 (90.1%) 0.38
Beta-blocker use 79 (84.0%) 85 (84.2%) 1.00
ACE inhibitor use 72 (76.6%) 84 (83.2%) 0.29
Calcium-channel blocker use 28 (29.8%) 27 (26.7%) 0.75
Diuretic agent use 48 (51.1%) 58 (57.4%) 0.39
Long-acting nitrate use 27 (28.7%) 27 (26.7%) 0.87
PRN nitroglycerine use 43 (45.7%) 40 (39.6%) 0.47
Fibrate use 16 (17.0%) 12 (11.9%) 0.32
Insulin use 45 (47.9%) 48 (47.5%) 1.00
Sulfonylurea/meglitinide use 39 (41.5%) 46 (45.5%) 0.66
Thiazolidinedione use 17 (18.1%) 10 (9.9%) 0.15
Metformin use 45 (47.9%) 58 (57.4%) 0.20
Other antidiabetic medication use 6 (6.4%) 8 (7.9%) 0.78MI for PCI and surgery. We deliberately adopted the
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of biasing the trial by the definition of periprocedural MI.
This resulted in a moderate risk for periprocedural MIs in
the surgery group (4%) and no periprocedural MIs for PCI.
This was accepted with the expectation of capturing
“harder” endpoints later in the study. An unintended con-
sequence was to exclude periprocedural MIs that occurred
with repeat revascularization (Table 2). At 2-year follow-up,
the composite endpoint would have been 18.4% in the
surgery arm and 32% in the PCI arm, using the 2007 universal
definitions of MI (Table 2). This 42.5% relative risk reduction
is virtually identical to our projections.
A second factor is our aggressive search for silent MIs.
Other studies have included silent MIs when discovered but
have not mandated serial electrocardiography and nuclear
studies. We believed that it was critical to identify and
accurately time as many silent MIs as possible in a diabetic
cohort. All of the silent MIs were found in the surgery arm.
Possible explanations include small number effects, a poten-
tial for surgical “denervation” to blunt symptoms, and
transforming larger MIs into smaller, asymptomatic ones.
Silent MIs accounted for one-third of the total nonfatal MIs
in the surgery arm, an effect that has not been reported
elsewhere. Our study might best be compared with others
with silent MIs excluded. Table 2 shows the risk for MI at
2 years when silent MIs are eliminated. The study would
have had power of 76.9% for the composite endpoint
eliminating silent MIs and using the 2007 universal defini-
Primary and Secondary EndpointsTable 2 Primary and Secondary Endpoints
1-Year Occurrence R
Endpoint CABG (n  97) PC
Death or nonfatal MI 16.9 (54%)* 1
All-cause death 5.0 (62%)
Cardiac death 5.0 (62%)
All nonfatal MI 13.4 (54%)
Periprocedural MI 4.2 (91%)
Clinical MI 7.8 (58%)
Silent MI 1.4 (73%)
Stroke 1.2 (82%)
Repeat revascularization 11.3 (56%) 1
Using universal definition of PCI periprocedural MI
Death or nonfatal MI 16.9 (54%) 1
All nonfatal MI 13.4 (54%)
Periprocedural MI 4.2 (91%)
Clinical MI 7.8 (58%)
Silent MI 1.4 (73%)
Using universal definition of PCI periprocedural MI
and no silent MIs
Death or nonfatal MI 14.7 (54%)* 1
All nonfatal MI 11.2 (54%)
Periprocedural MI 4.2 (91%)
Clinical MI 7.8 (58%)
*Number of patients at risk.
CI  confidence interval; HR  hazard ratio. All other abbreviations as in Table 1.tion for periprocedural MIs.We looked for specific patient or angiographic character-
istics that contributed to a higher mortality with PCI. The
PCI arm contained more patients with previous PCI, a
slightly higher degree of average lesion stenosis, and slightly
longer average lesion length. Survival curves were reanalyzed
adjusting for these variables, with no effect on the results.
There were also more normal ventricular function scores in
surgical patients. Comparing the distribution of left ventric-
ular function in PCI survivors versus nonsurvivors reached
statistical significance (p 0.04), as did greater age (61.8 vs.
66.4 years, p  0.01). Among PCI patients, moderate to
severely impaired ventricular function resulted in mortality
of 28.3% as opposed to 11.4% with no or mild dysfunction
(relative risk: 2.49). There were trends toward greater
beta-blocker use (p  0.07) and lower body mass index (p
0.12) in the nonsurvivors. Surprisingly, SYNTAX score did not
affect outcomes in our patients. At baseline, the PCI arm
had a higher percentage of patients with low SYNTAX
scores than the surgical arm (Table 1), and the balance of
SYNTAX scores among PCI survivors and nonsurvivors was
virtually identical (Table 3). Low numbers and short follow-up
limit our ability to make definitive statements about subsets
that fare worse with PCI.
Our patient population was deliberately chosen to max-
imize survival effects over time. Coordinators screened all
patients with diabetes presenting for diagnostic catheteriza-
tion. Patients who had no indications for revascularization
or who did not have territories at risk in the anterior wall
) 2-Year Occurrence Rate (%)
101) CABG (n  97) PCI (n  101) HR 95% CI
%) 18.4 (53%) 25.3 (31%) 0.89 0.47–1.71
%) 5.0 (62%) 21.0 (33%) 0.30 0.11–0.80
%) 5.0 (62%) 10.8 (32%) 0.53 0.16–1.77
%) 15.0 (53%) 6.2 (47%) 3.32 1.07–10.30
1%) 4.2 (91%) 0.0 (101%) — —
%) 7.8 (58%) 6.2 (47%) — —
1%) 5.3 (40%) 0.0 (101%) — —
0%) 1.2 (82%) 1.0 (100%) 1.03 0.06–16.49
%) 19.5 (26%) 18.9 (31%) 0.93 0.42–2.07
%) 18.4 (53%) 32.0 (26%) 0.72 0.39–1.35
%) 15.0 (53%) 16.3 (24%) 1.34 0.58–3.11
%) 4.2 (91%) 10.1 (26%) 0.72 0.20–2.57
%) 7.8 (58%) 6.2 (47%) 1.59 0.45–5.62
1%) 5.3 (40%) 0.0 (101%) — —
%) 14.7 (54%) 32.0 (26%) 0.59 0.30–1.15
%) 11.2 (54%) 16.3 (24%) 1.01 0.41–2.48
%) 4.2 (91%) 10.1 (26%) 0.72 0.20–2.57
%) 7.8 (58%) 6.2 (47%) 1.59 0.45–5.62ate (%
I (n 
0.6 (63
8.2 (70
4.5 (69
2.6 (62
0.0 (10
2.6 (62
0.0 (10
1.0 (10
1.6 (55
1.6 (63
4.8 (62
2.3 (75
2.6 (62
0.0 (10
1.6 (63
4.8 (62
2.3 (75
2.6 (62were excluded. Many patients eligible for PCI in BARI 2D
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left anterior descending coronary artery disease with or
without disease in 1 or both other territories. There had to
Figure 2 Composite Endpoint, All-Cause Mortality, and Nonfata
(A) Time to first occurrence of nonfatal myocardial infarction (MI) or death by treat
by treatment group: Kaplan-Meier estimate of survival function. (C) Time to first ocbe at least 1 territory with either a 70% angiographicstenosis or objective evidence of ischemia. Evidence of
ischemia included cardiac enzymes, stress testing, dynamic
electrocardiographic changes, flow wire, or intracoronary
group: Kaplan-Meier estimate of survival function. (B) Time to all-cause death
ce of nonfatal MI by treatment group: Kaplan-Meier estimate of survival function.l MI
ment
currenultrasound. This ensured that angiographically borderline
collection.
DES  drug-eluting stent. All other abbreviations as in Table 1.
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February 26, 2013:808–16 Coronary Revascularization in Diabetescases had a clear indication for revascularization. The
Fractional Flow Reserve Versus Angioplasty for Multivessel
Evaluation trial showed the importance of objective evi-
dence of flow restriction in borderline stenoses (20). Our
trial focused on high-risk patients, those with diabetes in
whom aggressive coronary disease progression was com-
bined with severe existing lesions. We expected to have the
greatest difference in survival with revascularization com-
pared with aggressive medical therapy, in contrast to BARI
2D, in which medical management was a reasonable option.
Relaxing our entry criteria to include more patients would
have also reduced the expected differences in survival and
thus necessitated a much larger sample size to identify a
survival effect of revascularization.
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APPENDIX
For a complete listing of the members of the VA CARDS, please see the
online appendix.
